{"filing":{"accession_number":"0001193125-26-255479","cik":"0001645460","ticker":"CUE","company_name":"Cue Biopharma, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"cue-20260601.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526255479/cue-20260601.htm"},"events":[{"id":7172,"run_id":6291,"accession_number":"0001193125-26-255479","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Stockholders approved three proposals at a Special Meeting held in May 2026: (1) issuance of warrants in connection with a licensing transaction and private placement, (2) adoption of the 2026 Stock Incentive Plan, and (3) adjournment of the meeting if necessary.","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3982,"accession_number":"0001193125-26-255479","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Stock Incentive Plan, a compensatory arrangement for directors and officers. This is a classic Item 5.02(e) event involving adoption of an equity compensation plan subject to shareholder vote, which materially affects the registrant's ability to grant equity awards and retain talent.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:24:45.460736+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3983,"accession_number":"0001193125-26-255479","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from a Special Meeting under Item 5.07. The filing reports the certified vote tallies for three proposals: (1) approval of warrant issuance in connection with a May 2026 licensing transaction and private placement, (2) approval of the 2026 Plan, and (3) approval of meeting adjournment. The warrant issuance approval is material as it relates to dilutive equity issuance tied to a licensing transaction, and the equity plan approval is a standard material governance matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:24:45.460736+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3982,"accession_number":"0001193125-26-255479","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Stock Incentive Plan, a compensatory arrangement for directors and officers. This is a classic Item 5.02(e) event involving adoption of an equity compensation plan subject to shareholder vote, which materially affects the registrant's ability to grant equity awards and retain talent.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:24:45.460736+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-06-03"},{"id":3983,"accession_number":"0001193125-26-255479","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from a Special Meeting under Item 5.07. The filing reports the certified vote tallies for three proposals: (1) approval of warrant issuance in connection with a May 2026 licensing transaction and private placement, (2) approval of the 2026 Plan, and (3) approval of meeting adjournment. The warrant issuance approval is material as it relates to dilutive equity issuance tied to a licensing transaction, and the equity plan approval is a standard material governance matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:24:45.460736+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-06-03"}]}